DGX vs STRO · P/E 22, rev $9.87B vs rev $62.0M
Quest Diagnostics Incorporated (DGX) versus Sutro Biopharma (STRO) — a side-by-side from cached financials, not a winner call.
Quest Diagnostics Incorporated (DGX) is a diagnostics & research company listed on US.
Sutro Biopharma (STRO) is a biotechnology company listed on NASDAQ.
Latest reported DGX revenue for 2024-12-31 was $9.87B. Net income was $921.0M. Revenue was up 6.7% from 2023-12-31 to 2024-12-31. DGX currently screens at market cap $19.94B and trailing P/E 22.4.
Latest reported STRO revenue for 2024-12-31 was $62.0M. Net income was -$227.5M. Revenue was down 59.6% from 2023-12-31 to 2024-12-31. STRO currently screens at market cap $470.8M.
DGX currently screens at market cap $19.94B and trailing P/E 22.4. STRO currently screens at market cap $470.8M.
Not investment advice. Open the DGX and STRO stock pages for the full models.
Not investment advice.